REDWOOD CITY, Calif.,
April 30, 2015 /PRNewswire/ --
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Urology
Practice, an official journal of the American Urological
Association (AUA), published positive results from the first
decision impact study of the Oncotype DX® prostate cancer test.
Results showed that use of the test substantially increased the
number of men who can consider active surveillance, while
increasing physician confidence in their treatment
recommendations.
"By providing a way to refine risk assessment based on a
patient's specific tumor biology, this genomic test allows
physicians to confidently determine the best individualized
treatment option for each man," said Ketan
K. Badani, M.D., who led the study while at Columbia University, and who is currently vice
chairman of Urology and Robotic Operations at Mount Sinai Health
System, New York.
This prospective study involving 158 newly diagnosed prostate
cancer patients showed that incorporation of the Genomic Prostate
Score (GPS) changed modality and/or intensity of treatment
recommendations in 26 percent of patients across multiple urology
practice settings. The NCCN low risk group showed the greatest
absolute recommendation change of 37 percent. The increase in
recommendations for active surveillance was 24 percent.
Additionally, 85 percent of urologists were more confident in their
treatment recommendation following review of the GPS.
"These data underscore the significant impact that Oncotype DX
has on treatment recommendations and suggest that use of our assay
will decrease the burden of low-risk prostate cancer by helping
physicians reduce unnecessary immediate treatment while helping
identify those who would benefit from invasive treatment at
diagnosis," said Phil Febbo, M.D.,
chief medical officer, Genomic Health. "We believe this
publication, along with our second clinical utility study that has
been accepted for publication, further strengthens our efforts to
secure reimbursement."
The study was conducted in collaboration with academic and
community practices at Columbia
University, Delaware Valley Urology and Orange County
Urology.
Results from the second Oncotype DX prostate cancer test
decision impact study have been accepted for future publication in
Urology Practice.
About Oncotype DX
The Oncotype DX® portfolio of
breast, colon and prostate cancer tests applies advanced genomic
science to reveal the unique biology of a tumor in order to
optimize cancer treatment decisions. The Oncotype DX
prostate cancer test identifies low- to intermediate-risk patients
eligible for active surveillance, as well as those who may benefit
from immediate invasive treatment by predicting disease
aggressiveness. With half a million patients tested in more than 70
countries, Oncotype DX testing has redefined personalized
medicine by making genomics a critical part of cancer diagnosis and
treatment. To learn more about the Oncotype DX prostate
cancer test, visit: www.OncotypeDX.com
or www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ:
GHDX) is the world's leading provider of genomic-based diagnostic
tests that address both the overtreatment and optimal treatment of
early-stage cancer, one of the greatest issues in healthcare today.
The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive
amounts of genomic data into clinically-actionable results for
treatment planning throughout the cancer patient's journey, from
diagnosis to treatment selection and monitoring. The company
is based in Redwood City, California, with European
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the attributes and benefits
of the company's tests to physicians, patients and payors; and the
belief that publication of the study and a second clinical utility
study will lead to increased usage and secure reimbursement.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: the risks and uncertainties associated with the
regulation of the company's tests; the results of clinical studies;
the applicability of clinical study results to actual
outcomes; the risk that the company may not obtain or
maintain sufficient levels of reimbursement, domestically or
abroad, for its existing tests and any future tests it may develop;
the risks of competition; unanticipated costs or delays in research
and development efforts; the company's ability to obtain capital
when needed and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the
risks set forth in the company's annual report on Form 10-K for the
year ended December 31, 2014. These forward-looking statements
speak only as of the date hereof. Genomic
Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-announces-publication-of-oncotype-dx-prostate-cancer-test-decision-impact-study-in-urology-practice-supporting-wider-adoption-and-reimbursement-300074766.html
SOURCE Genomic Health, Inc.